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We  previously  reported  the  nano-surface  and  molecular-orientation  limited  (nSMOL)  proteolysis,  which
is a novel  method  for selective  quantitation  of  monoclonal  antibody  Fab.  The  nSMOL  strategy  is a
Fab-selective  limited  proteolysis  which  utilizes  the  size  difference  between  the  protease  nanoparticle
(200  nm)  and  the  antibody  resin  pore  (100  nm).  Here,  we  applied  this  method  to a fully  validated  LCMS
analysis  of  Nivolumab  in human  plasma.  The  immunoglobulin  fraction  was  collected  using  Protein  A
resin,  which  was then  followed  by  nSMOL  reaction  using  the  FG  nanoparticle  surface-immobilized  trypsin
under a nondenaturing  physiological  condition  at  50 ◦C for 7 h. After  removal  of resin  and  nanoparticles
by  ﬁlter  centrifugation,  signature  peptides  were  separated  using  the  ODS  column  liquid chromatogra-
phy.  The  signature  peptide  ASGITFSNSGMHWVR  from  Nivolumab  complementarity-determining  region
(CDR) and  the P14R  internal  standard  were  simultaneously  quantiﬁed  by multiple-reaction  monitoring
(MRM)  LCMS,  with  parent  m/z  550.8  > fragment  m/z  661.5  (y11  2+).  The  lower  limit  of  quantiﬁcation
(LLOQ) of  Nivolumab  using  the nSMOL  method  was  0.977  g/ml,  with  a  linear  dynamic  range  of from
0.977  to 250  g/ml.  The  intra-  and  inter-assay  precision  of  LLOQ,  low  quality  control  (LQC),  middle  qual-
ity  control  (MQC),  and  high  quality  control  (HQC)  were  7.56–17.9%  and  15.6%, 6.99–9.25%  and  7.51%,
2.51–8.85%  and  8.01%,  and  4.78–7.33%  and  6.75%,  respectively.  Our  study  demonstrates  that  the  nSMOL
bioanalysis  can be  utilized  as  a  reliable  method  for  clinical  pharmacokinetic  studies  of Nivolumab  and
other antibody  drugs.
ublis© 2016  The  Authors.  P
. Introduction
Programmed cell death-1 (PD-1, CD279), originally identiﬁed
y Honjo et al. [1], is a type-1 transmembrane immunoreceptor
elated to the CD28/cytotoxic T-lymphocyte-associated antigen 4
CTCL-4) family, which negatively regulates the immune response
athways in T-cells [2,3]. This immunological signiﬁcance led to
ts numerous clinical beneﬁt such as for autoimmunity, infec-
ious elements, and cancer immunotherapies [4]. It is conceivable
Abbreviation: nSMOL, nano-surface and molecular-orientation limited proteol-
sis.
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that there are three stages of immune editing systems in can-
cer cells: elimination, equilibrium, and escape [5]. Therefore,
blockade of the inhibitory antitumor T-cell response called the
immune checkpoint has been a major therapeutic target for
many cancer eradication. A highly speciﬁc monoclonal antibody
Nivolumab is a fully human IgG4 monoclonal antibody targeting
PD-1 and it is approved by the Food and Drug Administration
in 2011 as a new drug for melanoma. T-cells assume deﬁnitive
roles in immune cell-mediated cancer immunity via a complex
cell-to-cell signaling. Long-term cancer controls is one clinical
outcome achieved by immune checkpoint inhibitors, by regu-
lating the accelerated and/or suppressive immune balance. This
mechanism of immunotherapy has also received great atten-
tion for the treatment of non-small-cell lung [6–8], renal cell
carcinomas [9], ovary [10], bladder [11], and prostate cancers
[12], glioblastoma [13], lymphoma [14], and many other tumour
types.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Multiple sequence alignment of Nivolumab amino acid sequence by ClustalW analysis.
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imino acid sequences of four monoclonal antibodies of Nivolumab, Tremelimumab
rea  shows the matched sequence as common frameworks, and gray is to highlight s
osition. (For interpretation of the references to color in this ﬁgure legend, the read
However, Nivolumab and other immune checkpoint agents
re known to cause several immune-related adverse events such
s dermatological, gastrointestinal, endocrine, hepatic, neurolog-
cal, and other effects on other organs [15–17]. It is challenging
o address the precision immunotherapy for cancers due to the
omplexity of diverse immune interactions. Thus, identiﬁcation
f predictive and pharmacodynamic biomarkers or marker pan-
ls for drug efﬁcacy will be crucial for a more effective cancer
mmunotherapy [18]. We  expect that an overall clinical pharma-
okinetics (PK) can be used as a good indicator for drug efﬁcacy
nd for predicting the effects on the immune response. However,
ow PK ﬁndings of these inhibitors may  translate to their clinical
utcomes is yet to be determined.
In the ﬁeld of clinical PK, ligand binding assay (LBA) is currently
he ﬁrst choice for quantitating therapeutic antibodies. However,
n some cases, LBA is not a reasonable method for antibodyumab, and Ramucirumab were aligned in (a) heavy chain and (b) light chain. Black
 amino acids. The red underline is shown to highlight the selected signature peptide
eferred to the web version of this article.)
quantitation. For example, neutralizing antibodies called anti-
drug antibodies (ADA) inhibit speciﬁc binding of antigen to drugs,
contributing to unexpected errors [19]. Furthermore, species-
speciﬁcity can cause limitation in translating ﬁndings obtained
using preclinical animal models into clinical studies in human.
Currently, cancer care utilizes combined chemotherapy strategies
using next generation molecular target compounds, antibodies, and
antibody-drug conjugates (ADC). Therefore, a more selective, sensi-
tive, and universal technology independent of a variety of antibody
agents will be desirable. Nivolumab is a fully human antibody; thus,
an accurate quantitation of signature peptides with a complete
structural determination is especially important since the speciﬁc
regions of antibody drugs are shorter than those of the endogenous
immunoglobulins with high sequence homology. Recently, liquid
chromatography-triple quadrupole mass spectrometry (LC-TQMS)
was applied to quantitate therapeutic antibodies in biological ﬂuid.
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CMS is a more selective and sensitive method to quantitate the
ntibody speciﬁc regions. Further, it allows for multiplex assay
evelopment in a more shorter period of time, without the has-
le of speciﬁc collection and detection antibodies in LBA method
20,21].
However, to develop LCMS at the level of regulated bioanalysis,
ecessary improvements will need to be done for greater preci-
ion and accuracy, dynamic range, and universal applicability for
ntibody drugs. Plasma is a complex biological mixture, and tryp-
ic peptides from this matrix are large excess analytes for LCMS.
xcess peptide mixtures and protease contamination can cause
onization suppression, carryover, noise elevation, lower dynamic
ange and retention time reproducibility, and column sustainabil-
ty. To overcome these issues, we recently reported a novel method
or selective proteolysis of the Fab by limiting protease access to
he substrate, which we termed the nano-surface and molecular-
rientation limited (nSMOL) proteolysis [22]. The nSMOL chemistry
as designed as a solid–solid proteolysis as follows: (1) protease
eaction on a uniform nanoparticle surface to raise the accessibility
o the substrate; (2) Fc immobilization onto the resin via Protein
, such that the Fab is oriented outward to the reaction solution;
nd (3) Fab-selective proteolysis by making use of the difference
n the protease nanoparticle diameter (200 nm) and the antibody
esin pore (100 nm). The nSMOL has allowed us to minimize sam-
le complexity while maintaining the speciﬁcity of peptides in
he complementarity-determining region (CDR). Furthermore, this
ethod has allowed for effective proteolysis on Fab by using a
ondenaturing physiological condition, absence of extra trypsin
ontamination in the analyte, absence of further peptide puriﬁca-
ion such as solid-phase extraction, and independent of a variety of
ntibodies. In this study, we demonstrate a validated LCMS analysis
f Nivolumab in plasma using the nSMOL [23,24].
. Materials and methods
.1. Reagents
Glycidyl methacrylate (GMA)-coated nano-ferrite particle FG
eads with surface activation by NHS group was purchased from
amagawa Seiki (Nagano, Japan). Toyopearl AF-rProtein A HC-
50F resin was from Tosoh (Tokyo, Japan). Nivolumab (OPDIVO)
as purchased from Ono Pharmaceutical (Osaka, Japan). Individ-
al male and female control human plasma (EDTA-2K treated) was
rom Kohjin Bio (Saitama, Japan). Trypsin gold was from Promega
Fitchburg, WI). n-octyl--d-thioglucopyranoside (OTG) was from
ojindo Laboratories (Kumamoto, Japan). P14R internal standard
ynthetic peptide was from Sigma Aldrich (St. Louis, MO). Ultrafree-
C GV centrifugal ﬁlter was from Merck Millipore (Billerica, MA).
ther reagents, buffers, and solvents were from Sigma-Aldrich and
ako Pure Chemical Industries (Osaka, Japan).
.2. Peptide structure identiﬁcation of Nivolumab peptides
Two microlitre of Nivolumab (20 g) was digested using 1 g
f trypsin in 150 l of 25 mM tris–HCl buffer (pH 8.0) contain-
ng 1 mM tris(2-carboxyethyl)phosphine-HCl salt (TCEP) at 37 ◦C
or 16 h. Trypsin digestion was quenched by adding 10% formic
cid solution at a ﬁnal concentration of 0.5%. For nSMOL reactions,
0 g of Nivolumab was collected with 10 l of PBS-substituted
F-rProtein A resin (50% slurry) with gentle vortexing at 25 ◦C for
0 min. Protein A resin was recovered on an Ultrafree ﬁlter, washed
wice using 300 l of PBS by centrifugation (10,000g for 1 min), and
ubstituted with 150 l of 25 mM tris–HCl (pH 8.0). nSMOL reac-
ion was carried out using 1 g of trypsin on FG-beads with gentle
ortexing at 37 ◦C for 16 h in saturated vapour atmosphere. After B 1023-1024 (2016) 9–16 11
proteolysis, reaction was stopped by adding 10% formic acid at a
ﬁnal concentration of 0.5%. The peptide solution was  collected by
centrifugation (10,000g for 1 min) to remove Protein A resin and
trypsin FG-beads. Structure of tryptic peptides from Nivolumab
were analysed by high-resolution liquid chromatography-linear
ion trap time-of-ﬂight MS  (Nexera X2 ultra high performance liq-
uid chromatograph and LCMS-IT-TOF, Shimadzu, Kyoto, Japan), and
fragment ions were assigned using an in-house Mascot server and
Distiller with Nivolumab amino acid sequence information (Matrix
Science, London, UK). The LCMS conditions were as follows: sol-
vent A, 0.1% aqueous formic acid; solvent B, acetonitrile with 0.1%
formic acid; column, L-column2 ODS, 2.1 × 150 mm,  2 m,  10 nm
pore (Chemicals Evaluation and Research Institute, Tokyo, Japan);
column temperature, 50 ◦C; ﬂow rate, 0.2 ml/min; gradient pro-
gram, 0–5 min: %B = 3, 5–35 min: %B = 3–30 gradient, 35–46 min:
%B = 95, 46–55 min: %B = 3. MS  and MS/MS  spectra were obtained
using desolvation line and heat block at 200 ◦C, respectively. Neb-
ulizer nitrogen gas ﬂows were set to 1.5 l/min. Drying gas pressure
was 100 kPa. Ion accumulation time was  30 ms  for MS, and 70 ms
for MS/MS  analysis. MS/MS  analysis was performed using the auto-
mated data dependent mode. Ar pulse time into the ion trap cell
was 125 s. The electrode of collision-induced dissociation (CID)
cell was  set at −1.5 V.
2.3. Prediction of Nivolumab signature peptides
Amino acid sequences of antibody drugs were obtained from
Kyoto Encyclopedia of Genes and Genomes (KEGG) DRUG. Multi-
ple alignment was  performed using the amino acid sequence of
Nivolumab (KEGG DRUG entry D10316), Tremelimumab (D06657),
Ipilimumab (D04603), and Ramucirumab (D09371) by ClustalW
algorithm on GENETYX software (GENETYX, Tokyo, Japan). In this
analysis, theoretical tryptic peptides containing the CDR sequence,
amino acid substitution, positions of conserved cysteine residues,
and insertion or deletion of amino acids were aligned.
2.4. Condition setting of multiple reaction monitoring for
Nivolumab peptides
The peptide quantitation was analysed using an LC–electrospray
ionization-MS (LC–ESI-MS) with triple quadrupole (Nexera X2
and LCMS-8050, Shimadzu). The LCMS conditions were as fol-
lows: solvent A, 0.1% aqueous formic acid; solvent B, acetonitrile
with 0.1% formic acid; column, Shim-pack GISS C18, 2.1 × 50 mm,
1.9 m,  20 nm pore (Shimadzu); column temperature, 50 ◦C; ﬂow
rate, 0.4 ml/min; gradient program, 0–1.5 min: %B = 1, 1.5–4.5 min:
%B = 1–40 gradient, 4.5–5.5 min: %B = 95 with ﬂow rate 1 ml/min,
5.5–6 min: %B = 1 with ﬂow rate 1 mi/min, and 6–6.5 min: %B = 1.
MS spectra were obtained with ESI probe temperature, desolva-
tion line, and heat block at 300 ◦C, 250 ◦C and 400 ◦C, respectively.
Nebulizer, heating, and drying nitrogen gas ﬂows were set to 3, 10,
and 10 l/min, respectively. The dwell time was set to 10 ms  for each
transition. MRM  monitor ions of peptide fragments were imported
from the measured values of structure-assigned fragments by high-
resolution LCMS analysis. CID Ar partial pressure in the Q2 cell was
set to 270 kPa. The electrode voltage of Q1 pre bias, collision cell Q2,
Q3 pre bias, and parent and fragment ion m/z were optimized using
the LabSolution software (Shimadzu). For MRM  transition, one frag-
ment ion of b- or y-series was selected for quantitation, and two
ions for structural conﬁrmation according to the optimized MRM
ion yield.2.5. Validation sample preparation of Nivolumab analysis
In the current study, we performed a bioanalytical validation
of Nivolumab in plasma using the nSMOL method as described
1 atogr. B 1023-1024 (2016) 9–16
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Fig. 2. Veriﬁcation of dilution interference.
Nivolumab tryptic peptides were quantitated by nSMOL in human plasma. Rep-
resentative calibration curves of (a) ASGITFSNSGMHWVR, which showed good
correlation with Nivolumab concentrations, and (b) LLIYDASNR, with no correla-
tion to Nivolumab concentrations demonstrating competition from endogenous2 N. Iwamoto et al. / J. Chrom
n our previous report with a minor improvement [22]. Brieﬂy,
ll validation sample sets were prepared and stored at −20 ◦C or
80 ◦C for 24 h or longer before each validation assay. A 20 l
liquot of Nivolumab-spiked human plasma was diluted 10-fold
n PBS (pH 7.4) containing 0.1% OTG. The Ig fraction was collected
ith 50 l of PBS-substituted AF-rProtein A resin (50% slurry) with
entle vortexing at 25 ◦C for 15 min. Protein A resin was  collected
nto Ultrafree ﬁlter and washed twice with 300 l PBS containing
TG, centrifuged (10,000g for 1 min), and substituted with 150 l
f 25 mM tris-HCl (pH8.0) containing 10 pmol/ml P14R and 2 mM
CEP. nSMOL proteolysis was carried out using 25 g trypsin on
G-beads with gentle vortexing at 50 ◦C for 7 h in saturated vapour
tmosphere. After nSMOL, reaction was stopped by adding 10%
ormic acid at a ﬁnal concentration of 0.5%. The peptide solution
as collected by centrifugation (10,000g for 1 min) to remove Pro-
ein A resin and trypsin FG-beads. These analytes were transferred
nto low protein binding polypropylene vials for LCMS analysis. The
oncentration of Nivolumab in plasma samples was set from 0.977
o 250 g/ml with two-fold serial dilution for nine calibration sam-
les. The concentrations of lower limit of quantiﬁcation (LLOQ),
ow quality control (LQC), middle quality control (MQC), and high
uality control (HQC) were set to 0.977, 2.93, 23.4, and 200 g/ml,
espectively.
. Results
.1. Structural conﬁrmation of Nivolumab peptides by
CMS-IT-TOF MS  and ClustalW analysis
The identiﬁcation of tryptic Nivolumab peptides was  performed
sing a high-resolution LC-TOF MS/MS  analysis and Mascot server.
ive peptides from the heavy chain and three from the light chain
n Fv were assigned with signiﬁcant Mascot score, and summa-
ized in Table 1. Peptide regions were shown as ClustalW alignment
esults of four fully human therapeutic antibodies (Fig. 1). To select
ignature peptides, we have established a criteria in our previous
eport: peptides with 8–15 amino acid sequences, with no missed
leavage, no cysteine residue, and exclusion of the vicinity of the
onserved disulphide bonding on the framework structure. Opti-
ized MRM  transitions of each peptide are shown in Table 2, with
ne fragment for quantitation and an additional two fragments for
tructural conﬁrmation.
.2. Nivolumab peptides interference from human plasma
To determine interference of Nivolumab peptides from
uman plasma, each candidate peptide was analysed using
.69–37.5 g/ml of sample with two-fold serial dilution in plasma.
ot all CDR peptides can be used as the speciﬁc peptide for nSMOL
ioanalysis, due to the exceedingly diverse set of CDR sequences
n endogenous immunoglobulins. The peptide ASGITFSNSGMH-
VR  (MW  1649.8) was selected as the signature Nivolumab
eptide as we showed no interference from human plasma and
 good correlation with Nivolumab concentrations (Fig. 2a). In con-
rast, for example of LLIYDASNR peptide, showed no correlation
o Nivolumab concentrations demonstrating a competition from
ndogenous immunoglobulins (Fig. 2b).
.3. Bioanalytical validation
The bioanalytical method was validated according to the
uideline on Bioanalytical Method Validation in Pharmaceuti-
al Development from Notiﬁcation 0711-1 of the Evaluation and
icensing Division, Pharmaceutical and Food Safety Bureau, the
inistry of Health, Labour and Welfare, dated July 11, 2013 for lowimmunoglobulin are shown.
molecular weight drug compounds. The validation results of this
study are summarized in Supporting information.
3.3.1. Selectivity
For the individual human plasma controls from three males
and three females, no interference peak in the MRM  chro-
matograms were detected for the ASGITFSNSGMHWVR signature
Nivolumab peptide. Minimal response was  observed from inter-
fering substance at the retention time of 3.75 min  corresponding
to the signature Nivolumab peptide. Representative MRM  chro-
matograms of the signature Nivolumab peptide are shown in
Fig. 3.
3.3.2. Matrix effect
Individual plasma samples from three males and three females
were analysed for matrix effect test at the LQC and HQC concentra-
tions. The response ratio of Nivolumab peptide in plasma prior to
each sample preparation step was  compared to that of PBS. Matrix
factors of P14R-corrected value at LQC and HQC were 9.72% and
7.27%, respectively, which were within the accepted criteria of pre-
cision (CV) of <15% (Table S1 in Supporting information).
3.3.3. Carryover
The carryover test was performed by analysing three replicates
for Nivolumab peptide and one run for P14R immediately after the
high concentration (250 g/ml) analysis. The carryover was cal-
culated as percent response in the blank plasma relative to the
preceding sample. In nSMOL analysis, carryover was  observed at
0.151–0.172% for the Nivolumab peptide and no carryover was
observed for P14R, conﬁrming minimal levels of carryover inﬂu-
encing our analysis (Table S2 in Supporting information).
3.3.4. Linearity and calibration standard
The linearity of nSMOL protocols was  evaluated by analysing
nine calibration standards (zero sample, 0.977, 1.95, 3.91, 7.81,
15.6, 31.3, 62.5, 125, and 250 g/ml) using the linear regression
model. The calibration plot of weighting was done using the 1/area2
method. The calibration ﬁt formulas of the triplicate runs were
Y = 0.0627X + 0.0211 (r = 0.997), Y = 0.0585X + 0.00507 (r = 0.997),
and Y = 0.0750X + 0.0434202 (r = 0.996) (r: correlation coefﬁcient).
The accuracy at LLOQ was  91.9–97.0%, and at other concentrations
were 91.1–111% (Table S3 in Supporting information).
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Table  1
Identiﬁed peptides from Nivolumab using the in-house Mascot analysis.
No. Observed m/z Sequence Region
1–16 796.9217 *QVQLVESGGGVVQPGR (*N-term Q as pyro-Glu) N-term of H-chain
24–38 550.5983 ASGITFSNSGMHWVR CDR1 of H-chain
44–57  593.6439 GLEWVAVIWYDGSKR CDR2 of H-chain
59–65  423.2042 YYADSVK CDR2 of H-chain
77–87  668.8559 NTLFLQMNSLR CDR2 of H-chain
1–18  633.3453 EIVLTQSPATLSLSPGER N-term of L-chain
25–45  784.7257 ASQSVSSYLAWYQQKPGQAPR CDR1 of L-chain
46–54  532.7885 LLIYDASNR CDR2 of L-chain
Table 2
Optimal MRM  transition of signature candidate peptides from Nivolumab by nSMOL analysis.
Selected peptide Optimal MRM  condition Role
Transition mass ﬁlter [m/z] Q1 [V] Collision [V] Q3 [V]
P14R (internal
standard)
512.1 → 292.3 (b3 +) −38 −20 −20 Quantitation
512.1 → 389.3 (b4 +) −38 −16 −28 Structure
512.1 → 660.4 (b6 +) −38 −17 −24 Structure
pQVQLVESGGGVVQPGR 797.1 → 329.3 (y3 +) −22 −20 −24 Quantitation
797.1 → 457.3 (y4 +) −22 −21 −17 Structure
797.1 → 551.3 (y5 +) −36 −26 −40 Structure
ASGITFSNSGMHWVR 550.8 → 661.5 (y11 ++) −24 −18 −24 Quantitation
550.8 → 746.4 (y13 ++) −26 −16 −28 Structure
550.8 → 785.4 (y6 +) −26 −25 −30 Structure
GLEWVAVIWYDGSKR 593.8 → 805.0 (y13 ++) −28 −17 −30 Quantitation
593.8 → 740.4 (y12 ++) −26 −18 −40 Structure
593.8 → 597.8 (y10 ++) −28 −17 −22 Structure
YYADSVK 423.3 → 519.4 (y5 +) −20 −16 −26 Quantitation
423.3 → 682.4 (y6 +) −20 −18 −26 Structure
423.3 → 333.1 (y3 +) −20 −20 −24 Structure
NTLFLQMNSLR 669.0 → 1008.6 (y8 +) −30 −24 −30 Quantitation
669.0 → 861.5 (y7 +) −30 −25 −32 Structure
669.0 → 748.4 (y6 +) −30 −25 −28 Structure
EIVLTQSPATLSLSPGER 949.7 → 1127.7 (y11 +) −26 −36 −44 Quantitation
949.7 → 458.3 (y4 +) −26 −32 −17 Structure
949.7 → 545.3 (y5 +) −26 −30 −28 Structure
ASQSVSSYLAWYQQKPGQAPR 785.0 → 940.6 (y16 ++) −36 −25 −36 Quantitation
785.0 → 1033.8 (y18 ++) −36 −25 −30 Structure
785.0 → 625.3 (y6 +) −36 −36 −32 Structure
3
p
N
a
p
a
a
a
8
t
6
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aLLIYDASNR 532.9 → 838.5 (y7 +) −24 
532.9 → 725.4 (y6 +) −24 
532.9 → 447.3 (y7 +) −24 
.3.5. Precision and accuracy in inter- and intra-assays
Precision and accuracy were determined by analysis of human
lasma validation sample at LLOQ, LQC, MQC, and HQC of
ivolumab concentrations. The intra-day and inter-day precision
nd accuracy were determined by analysing ﬁve sets of QC sam-
les at four concentration levels on three different days. Precision
nd accuracy data were: run 1, 92.7% and 17.9% at LLOQ, 102–112%
nd 7.11–9.25% at other concentrations; run 2, 109% and 11.2%
t LLOQ, 99.0–103%, 2.51–7.86% at other concentrations; run 3,
7.0% and 7.56% at LLOQ, 98.4–101%, 4.78–6.99% at other concen-
rations; intra-assay (N = 15), 96.1% and 15.6% at LLOQ, 101–105%,
.75–8.01% at other concentrations (Table 3).
.3.6. Lower Limit of Quantiﬁcation (LLOQ)
The LLOQ was deﬁned as the lowest concentration of the cali-
ration curve with acceptable precision and accuracy, which were
etermined to be 0.977 g/ml (Table S4). According to the pack-
ge insert of Nivolumab from the Pharmaceuticals and Medical
evices Agency (PMDA) of Japan, the Cmax concentrations of
ivolumab Phase I trial (CA209001) in a single-dose administration
or melanoma cancer patients were 6.7, 16.0, 60.0, and 196.3 g/ml
or 0.3, 1, 3, and 10 mg/kg dose, respectively, indicating that the
SMOL quantitation was sufﬁcient to cover Nivolumab clinical con-
entration spectrum in the plasma. Thus, the nSMOL method was
dequate to monitor PK of Nivolumab.−19 −32 Quantitation
−20 −38 Structure
−28 −22 Structure
3.3.7. Dilution integrity
The effect of dilution on the analysis of Nivolumab concentration
was assessed by preparing spiked validation human plasma at a
concentration of 500 g/ml. The 10- and 25-fold dilution of the ﬁve
validation samples were analysed within the calibration range. The
precision and accuracy of the diluted samples were 7.92% and 95.4%,
9.27% and 109%, for 10- and 25-fold dilutions, respectively. These
values were within the criteria of decision, suggesting an absence
of interference from dilution (Table S4 in Supporting information).
3.3.8. Stability
The stability following ﬁve freeze-thaw cycles at −20 ◦C and
−80 ◦C with at least 12 h of frozen time, short-term stability at room
temperature for 4 h prior to sample treatment, long-term stability
at −20 ◦C and −80 ◦C for 30 days, and processed sample stability at
5 ◦C for 24 and 48 h were demonstrated at the LQC and HQC con-
centrations. The accuracy of the initial value for ﬁve freeze-thaw
cycles at LQC and HQC in −20 ◦C was 95.6% and 96.1%, respectively,
and in −80 ◦C was  87.5% and 101%, respectively (Table 4).
4. DiscussionWe have developed a practical and versatile analytical method
to assess Nivolumab plasma concentration in patients. As demon-
strated by the present validation study, this method was able to
14 N. Iwamoto et al. / J. Chromatogr. B 1023-1024 (2016) 9–16
Table  3
Precision and accuracy.
Run Nominal concentration Concentration (g/ml)
0.977 2.93 23.4 200
1 Observed 0.786 2.60 26.9 193
0.725  3.32 23.8 216
0.918 3.11 29.1 200
1.14 2.84 23.8 208
0.957  3.05 27.4 232
Mean  0.906 2.98 26.2 210
SD  0.162 0.276 2.32 14.9
CV  (%) 17.9 9.25 8.85 7.11
Accuracy (%) 92.7 102 112 105
2 Observed 0.912 3.17 24.2 189
1.04  2.75 23.3 185
1.08  3.10 23.8 196
1.24  3.14 24.0 222
1.03  2.68 25.0 197
Mean  1.06 2.97 24.1 198
SD  0.119 0.233 0.605 14.5
CV  (%) 11.2 7.86 2.51 7.33
Accuracy (%) 109 101 103 99
3 Observed 0.900  3.21 22.2 202
0.877  3.09 23.7 187
0.781  2.75 21.5 191
0.780  2.75 24.3 211
0.910  2.94 25.5 193
Mean  0.850 2.95 23.4 197
SD  0.0642 0.206 1.60 9.42
CV  (%) 7.56 6.99 6.84 4.78
Accuracy (%) 87.0 101 100 98.4
Mean  (N = 15) 0.939 2.97 24.6 202
SD  (N = 15) 0.146 0.223 1.97 13.6
CV  (%) 15.6 7.51 8.01 6.75
Accuracy (%) 96.1 101 105 101
Table 4
Conﬁrmation of QC sample for stability.
Parameters for stability
studies
Concentrations of nivolumab in human plasma (g/ml)
2.93 200
Mean (g/ml) Accuracy (%) Mean (g/ml) Accuracy (%)
Stability in plasma during freeze (−20 ◦C) and thaw cycles
Cycle 5 2.73 95.6 183 96.1
Stability  in plasma during freeze (−80 ◦C) and thaw cycles
Cycle 5 2.62 87.5 211 101
Short-term stability in plasma for 4 h at room temperature
2.80 95.5 186 92.9
Long-term stability in plasma for 30 days at −20 ◦C
3.03 104 213 107
Long-term stability in plasma for 30 days at −80 ◦C
3.15 107 187 93.3
Processed sample stability in HPLC set at 5 ◦C
97.8
105
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cFor 24 h 2.87 
For  48 h 3.08 
rovide a robust determination of Nivolumab in human plasma.
ll concentration points have reproducibly passed the guideline
riteria for low molecular weight drug compounds. Especially men-
ioned, nSMOL approach has been even acceptable for the normal
reezing storage at −20 ◦C. These advantages will be expected to
upport for the broad clinical PK study. We  believe that this assay
s suitable for routine analyses of plasma Nivolumab concentration
o study the correlations between its PK proﬁle and drug efﬁcacy
nd/or adverse events in clinical practice, thereby aiding the devel-
pment of a precision medicine for patients receiving Nivolumab
lone or in combination with other anticancer agents.
The essence of cancer immunotherapy is to control the
mmune cell activity in a complex immune system by immune
heckpoint blockade. However, immune checkpoint inhibitors 184 92.1
 195 97.6
have been linked to side effects. Although various studies have
helped elucidate cancer immunity, a detailed mechanism-based
immunotherapy which also takes into account the complex tumour
microenvironment and diverse tumour tissue types will be neces-
sary.
Expression of PD-1 ligand (PD-L1, PD-L2) in some cancer cells
or in immune cells within the tumour microenvironment has been
strongly correlated to negative prognosis. The response rates of 44%
for PD-L1-positive tumours and 17% for PD-L1-negative tumours
were reported in a phase I trial of Nivolumab [4,25]. However,
these response rates did not translate to overall survivals [26]. To
decide the optimal efﬁcacy of immune checkpoint inhibitors, med-
ical oncologists will require a conventional tool to predict clinical
efﬁcacy and to manage adverse events.
N. Iwamoto et al. / J. Chromatogr.
Fig. 3. MRM  chromatogram of the signature Nivolumab peptide ASGITFSNSGMH-
WVR  and P14R in a selectivity test of the LLOQ sample.
The signature Nivolumab peptide peak ASGITFSNSGMHWVR (fragment m/s  661.5
from parent 550.8, retention time 3.75 min) was observed at the LQC (2.93 g/ml)
sample. The horizontal axis shows the retention time (min) and vertical axis shows
the  ion count (cps). The red lines show baseline of the assigned peak. Representative
chromatograms from (a) Nivolumab-spiked plasma of a male person, (b) Nivolumab-
spiked plasma of a female person, (c) control blank sample, (d) internal peptide P14R
(fragment m/z 292.3 from parent 512.1, retention time 3.35 min), and (e) blank sam-
ple of P14R were shown. (For interpretation of the references to color in this ﬁgure
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Ligon, L. Zhu, J.F. Grosso, S.Y. Kim, J.M. Timmerman, M.A. Shipp, P. Armand,
PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’segend, the reader is referred to the web version of this article.)
Recently, PK-guided treatment such that as by therapeutic drug
onitoring for cancer chemotherapy has gained an increasing level
f interest. This is due to the current lack of available tools besides
BA to determine plasma concentration of antibody drugs in a clin-
cal setting. Mass spectrometry has the potential to support the
K study of antibody agents because of its superior selectivity for
rug structure-indicated quantitation. nSMOL is an novel method
or the quantitation of antibody-speciﬁc CDRs from blood and tis-
ue homogenate, independent of a variety of antibody agents [22].
SMOL analysis will allow for accurate quantitation of antibody
gents in the blood with the additional beneﬁts of speciﬁc struc-
ure conﬁrmation and multiplex assay development. Based on our
ioanalytical validation study, we have shown that nSMOL can be
ufﬁciently used to determine Nivolumab clinical PK.
In conclusion, we have ﬁrst demonstrated a fully validated anal-
sis of Nivolumab in human plasma using nSMOL coupled with
C–MS/MS. This analytical approach can be applied to other mon-
clonal antibodies. Moreover, our study demonstrates that the
[ B 1023-1024 (2016) 9–16 15
nSMOL method can be expected in future clinical pharmacokinetic
studies for antibody drug development and therapy.
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